To further test the clinical validity of our dataset, we used the onco-type DX DCIS,20 COX2+P16+ Ki67,21,22 and 812-gene15 classifiers for risk of DCIS recurrence. Here, MKI67 is linked to ductal breast carcinoma in situ.